For over 50 years, the standard has been that Staph aureus bacteremia and endovascular infections must be treated with a bactericidal antibiotic, like beta lactams or vancomycin. A new study suggests that bacteriostatic antibiotic, like clindamycin, could be used to treat MRSA bacteremia.

Redeem your CPE or CME credit here!

References and resources: Guthridge I, Smith S, Law M, et al. Efficacy and Safety of Intravenous Lincosamide Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0034321. doi: 10.1128/AAC.00343-21. Epub 2021 Aug 17. PMID: 34125589.


Continuing Education Information:
Learning Objectives:
1. Identify if an uncomplicated patient with MRSA bacteremia may be eligible for bacteriostatic medications
2. Describe some of the advantages of using drugs like clindamycin in these patients

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-339-H01-P
Initial release date: 10/12/21
Expiration date: 10/12/2022
Complete CPE & CME details can be found here !

What's new?

• GameChangers Pharmacotherapy Podcast will release new episodes on Mondays starting 10/18/2021
• We are making it easier to claim CE Credit for listening each week! This October - we'll launch a simple, one membership option so you can get one-click CE redemption for GameChangers episodes.  
• Name changes! You'll notice the podcast show will change to CEimpact - you'll still get new GameChangers episodes released each week on Mondays. Keep listening here and your feed will automatically switch over to CEimpact on 10/18.

Follow CEimpact on Social Media:
LinkedIn
Instagram